STK17B

Across TCGA pan-cancer cohorts, STK17B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of STK17B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where STK17B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types STK17B is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

LUAD, CCRCC, and HNSC are the cancer types where STK17B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STK17B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.380	<.001	9	view →
CCRCC	Male	II,III,IV	+0.390	<.001	8	view →
HNSC	Male	All	+0.241	<.001	8	view →
LSCC	Female	All	+0.389	<.001	7	view →
PDAC	Male	II,III,IV	+0.730	<.001	6	view →
COAD	All	II,III,IV	−0.182	.002	6	view →
OV	All	All	+0.549	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

STK17B–LUAD

Open the LUAD breakdown →